Respiree, a Singapore-based health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, has announced the successful closing of a $11.6 million Series A financing round led by We Venture Capital and ClavystBio.

The firm said in a statement on Wednesday that the round also had participation from Adaptive Capital Partners, conversion of note securities from Mayo Clinic’s Mayo Foundation for Medical Research and from existing investors including Greenwillow Capital Management, Seeds Capital, and she1K angel investment.

The proceeds will support expansion of Respiree’s commercial team and U.S. presence, including company headquarters in Houston, Texas, at the Texas Medical Center (TMC) Innovation.

Founded in Singapore, Respiree is now executing its global strategy to expand into new markets worldwide.

The firm’s solutions are currently available in the U.S., Australia, and across Asia-Pacific (APAC).

The company recently announced a partnership with Roche Diagnostics to launch pilot programs across the Asia Pacific (APAC) region.

The company has also established key international partnerships with leading global healthcare providers to support its expansion across both acute and home healthcare settings.

A portion of the Series A funds will be used to strengthen operations with existing channel partners and accelerate the development of new business relationships.

Respiree also plans to expand its offerings into newer international markets including the Gulf Cooperation Council and Thailand.

“The digitalization of healthcare offers a powerful opportunity to improve outcomes and efficiency—but without the right tools, it risks overwhelming care systems, especially amid workforce shortages,” said Dr. Gurpreet Singh, Founder and Chief Executive Officer of Respiree.

“What we need is better use of data, not just more data. Our AI solutions enable timely interventions, reduce alarm fatigue, and support care quality,

“We’re now focused on scaling these tools to enhance the entire patient journey—from smarter triage to follow-up,” he added.

It is noted that Respiree’s AI platform seeks to support quicker, efficient and precise decision making in various healthcare settings by automating patient monitoring, care pathway management and clinical insight delivery.

“Respiree stands out in the market by providing a patient monitoring AI/machine learning (ML) + hardware solution with incredible performance, but also unmatched understanding and execution of clinical workflow integration,

“Their scientifically validated data and key partnerships position Respiree for a promising scale-up journey driven by an extremely execution-focused team,” said Louise Warme, Head of We Venture Capital.

Meanwhile, Anselm Tan, Digital Health & MedTech Lead, ClavystBio, said the firm’s investment in Respiree is central to its strategy of helping companies scale globally from and through Singapore.

“Their innovative AI-powered monitoring platform is set to enhance patient care and empower clinical teams with actionable insights,

“This further underscores our commitment to accelerating medtech innovations aimed at improving patient outcomes across care settings,” he added.

Dr. Wong Mun Yew, Managing Partner of Oriza Greenwillow Technology Fund, Respiree has achieved much since Greenwillow Capital Management first invested in February 2022 and continued to support the company in the convertible notes last year.

“We are incredibly encouraged by the commercialization of Respiree’s products and services in tier-one markets and look forward to being part of Respiree’s growth as it continues to transform patient care on a global scale,” he added.

Singapore’s healthtech startup Mito Health raises $2.2M in seed round